Drugs / 2-deoxyglucose
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00247403 | Oct 2005 → Jun 2008 | metastatic malignant neoplasm in the brain | University of Iowa | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00633087 | Nov 2006 → Mar 2011 | prostate cancer | Rutgers, The State University of New Jersey | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05314933 Comparator | Mar 2022 → Aug 2023 | nasopharyngitis | G.ST Antivirals GmbH | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2-deoxyglucose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00247403 ↗ |
| Known as | 2DG | “2-deoxyglucose (2DG)” NCT00247403 ↗ |
| Action | Inhibit | “This agent works by blocking the metabolism of glucose in the cells of the body.” NCT00633087 ↗ |
| Modality | Small molecule | “2-deoxy-D-glucose is a synthetic glucose analog and a potent inhibitor of glycolysis” PMID 40101848 ↗ Mar 2025 |
| Route | Oral | “30 mg/kg of 2-deoxyglucose administered orally on a daily schedule” NCT00633087 ↗ |